PRINCETON, NJ, January 12, 2015
EDDA Technology, a global leading provider in computer-assisted radiology and surgery solutions, announced that the company will be exhibiting at Arab Health 2015 in Dubai, United Arab Emirates. The company will showcase its award-winning IQQA® Platform and Product Suite, an innovative technology platform in imaging-guided cancer treatment.
The IQQA® Platform and Product Suite provides real-time, quantitative multimodality imaging solutions to support the entire patient management cycle, including early detection, treatment planning, intra-operative guidance and monitoring, and post-operative follow-up. IQQA® is currently being used by leading cancer centers worldwide, including King Faisal Specialist Hospital & Research Centre (KSA), Mayo Clinic (USA), Massachusetts General Hospital (USA), University of California San Francisco Medical Center (USA), University of Colorado Hospital (USA), as well as many other global luminary sites.
The company ‘s key highlight will be IQQA®-BodyImaging, which extends the proprietary fast and powerful 3D features in the IQQA® product portfolio to thoracic, abdominal and pelvic scans. Features such as virtual knife for surgery and virtual needle for interventional planning, monitoring and follow-up, provide comprehensive tools for precision treatment delivery and quantifiable patient assessment.
“We are excited to bring to Arab Health our IQQA® Platform and Product Suite, an offering that covers close to 50% of the world’s cancer incidences and also addresses key challenges related to the treatment of prevalent lung and liver cancers in the region,” said Dr. Jianzhong Qian, president and CEO of EDDA Technology, and fellow of the American Institute of Medical and Biological Engineering (AIMBE). “We are confident that the IQQA® innovative solutions will aid in meeting and exceeding the clinical needs and treatment challenges in the Arab health market and abroad.”
As part of IQQA® Product Suite, the company will also be demonstrating IQQA®-Liver Multimodality and IQQA®-Chest. IQQA®-Liver Multimodality has been proven to offer significant time-saving and improved patient care for liver cancer treatment in more than 15,000 cases worldwide since 2009. IQQA®-Chest has been shown in a prospective study to assist physicians with early detection, by increasing physicians’ detection sensitivity of small lung nodules on X-ray from 63.8% to 92.7% (Academic Radiology Journal 2008;15:571-575).
EDDA will be exhibiting in Booth Z4E27 in the US Pavilion at Arab Health 2015.
IQQA® for thoracic, abdominal,and pelvic applications in cancer treatment planning, monitoring and follow-up.
About EDDA Technology
EDDA Technology, Inc. is an innovative clinical solution provider in the rapidly growing field of imaging-guided cancer treatment. By adopting a “fully quantitative, real-time interactive” approach to multimodality imaging analysis and guidance, EDDA offers a series of next generation computer-assisted solutions to the entire patient management cycle, including enabling early detection and diagnosis, and enhancing efficiency and precision in treatment planning, guidance, monitoring, and follow-up. EDDA’s goal is to deliver, with broad accessibility, advanced imaging analytics technologies and services that improve clinical workflow and accuracy. EDDA is headquartered in Princeton, New Jersey, USA and has subsidiaries in China. IQQA® is a registered trademark of EDDA Technology. www.eddatech.com